Next-generation sequencing reveals mutations in RB1, CDK4 and TP53 that may promote chemo-resistance to palbociclib in ovarian cancer
Sign Up to like & getrecommendations! Published in 2019 at "Drug Metabolism and Personalized Therapy"
DOI: 10.1515/dmpt-2018-0027
Abstract: Abstract Because of the profound heterogeneity of ovarian cancer at the clinical, cellular and molecular levels, herein we discuss the molecular findings at the protein and genetic levels seen in our patient. Immunohistochemistry showed a… read more here.
Keywords: chemo resistance; resistance palbociclib; ovarian cancer; next generation ... See more keywords